Several celebrities from Elon Musk to Oprah have openly endorsed them
Landmark Results The Phase 2 results, presented at the American Diabetes Association (ADA) Scientific Sessions in June 2023 and simultaneously published in the New England Journal of Medicine and The Lancet, were transformative: Weight loss : Up to 24.2% mean weight reduction at 48 weeks in the obesity trial (12 mg group), the highest ever reported for a pharmaceutical agent Glycemic control : Up to 2.02% HbA1c reduction in the diabetes trial, with most participants at higher doses achieving non-diabetic HbA1c levels Liver fat : Up to ~82% relative reduction in liver fat content Tolerability : GI adverse event profile consistent with the incretin class
GLP-1 receptor agonists have been used to treat Type 2 diabetes for more than 15 years and for treatment of obesity for eight years, including Novo products such as semaglutide and liraglutide that have been on the market for more than 10 years, a spokesperson said
It continued to get worse
Grey market products may spend days or weeks in transit without adequate cold packaging
Regular blood glucose monitoring and appropriate dose adjustments of concomitant medications are essential preventive measures
